Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.33 |
| ▸ | CCR8 | P51685 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10504863 | 0.84 | CCR1 (0.50) | CCR1CCR8NOS3NOS2 | |
| SCHEMBL1020383 | 0.82 | TSHR (0.41) | — | |
| SCHEMBL30569550 | 0.82 | MAPT (0.35) | — | |
| SCHEMBL3578929 | 0.78 | BTK (0.39) | — | |
| SCHEMBL18554207 | 0.77 | PGK1 (0.34) | — | |
| SCHEMBL18554150 | 0.77 | NOTUM (0.42) | — | |
| SCHEMBL29257145 | 0.75 | HTR1A (0.36) | — | |
| SCHEMBL30218120 | 0.71 | BRD4 (0.51) | — | |
| SCHEMBL5951287 | 0.69 | CYP1A2 (0.52) | NOS2 | |
| SCHEMBL18554319 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080119492-A1 | Compositions and methods for treating cancer and other diseases characterized by abnormal cell proliferation | LEHN JEAN-MARIE | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119492-A1 | Compositions and methods for treating cancer and other diseases characterized by abnormal cell proliferation | TERT, MKI67, POT1 | CCR1 3447/4885CCR8 4116/4885NOS3 1964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.